Sign in
NBIX Stock Price, Chart, Stats & News
Neurocrine Biosciences, Inc.
Save
16.83B
Market cap
25.75x
Current P/E
21.83x
Forward P/E
NBIX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 98.18% |
Operating margin | 21.64% |
Pretax margin | 24.66% |
Net margin | 16.73% |
Effective tax rate | 32.15% |
ROA | 10.33% |
ROE | 16.67% |
D/E | 0.13x |
Interest coverage ratio | – |
NBIX valuation
P/E | 25.75x |
P/S | 4.50x |
P/B | 3.92x |
P/CF | 16.31x |
P/FCF | 17.20x |
P/OCF | 16.31x |
PEG | 2.25x |
EV multiple | 18.32x |
About
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.
Similar securities
Based on sector and market capitalization
Report issue